Author Archives: admin


Treatment of AML in Older Patients Almost At ‘The Holy Grail’ – Curetoday.com

Recent drug approvals in the acute myeloid leukemia (AML) space have allowed older patients with the disease to continue receiving less intensive therapies than their younger counterparts, while also providing them with improved outcomes.

Were almost at the holy grail where (we) have lower intensity therapy thats well tolerated, but that the response rates are higher, said Dr. Tapan Kadia, an associate professor in the department of leukemia at The University of Texas MD Anderson Cancer Center in Houston, in an interview with CURE. Theyre not reaching (the 85% seen) with intensive chemotherapy, but (theyre) much better.

Kadia recently presented on the topic of treating older patients with AML during CUREs Educated Patient Leukemia Summit and highlighted how its vastly different than treating younger, and more fit patients.

He explained how the incidence of AML increases as a person gets older and that 60% of people who receive a diagnosis are aged older than 60 years.

Because more than half of the patient population with AML is aged older than 60 years, Kadia stressed that treatment approaches should be individualized for each patient. And, he said, factors such as their comorbidities, age, ability to tolerate chemotherapy and whether they could be candidate for a stem cell or bone marrow transplant in the future should play a role in selecting which treatment option they receive.

The major point to get across (is) to characterize a leukemia and to provide a therapy thats best for that patient long term, he said.

Although younger patients with the disease tend to receive more intensive chemotherapy regimens, it is tougher to administer those same regimens to older patients because it can wipe out their blood cell counts and it is difficult to deliver in a safe way, Kadia explained. In addition, older patients are more likely to have comorbidities such as heart disease, diabetes or COPD, which must also be managed in an intensive chemotherapy setting.

In years past, the lower intensity therapies were more tolerable, but they were not associated with great response rates. However, with the recent Food and Drug Administration approval of Venclexta (venetoclax), overall response rates increased to 65% and complete remission rates now are in the range of 35% to 40% when combined with drugs such as decitabine or azacitidine), Kadia explained. He said that these regimens are associated with very, very good outcomes with a median survival of 14.5 months, and the older patients tolerate it better.

Typically, patients who have AML and are in remission undergo a stem cell transplant or bone barrow transplant. However, for an older patient, a transplant is too risky. Regardless, Kadia noted that their remission should be maintained. Maintenance therapy is then used in this population to keep their disease in remission. Maintenance therapy usually consists of low-intensity, long-term treatment that can maintain the diseases response and help prevent the leukemia from returning.

What most people need to realize is that most subsets of AML are incurable, he said. That means (the disease) will typically try to come back if not treated aggressively and long term. And so this maintenance therapy allows people to maintain remission once they have achieved it.

We have really had a revolution in the treatment of AML, where previously we only had two or three drugs to treat AML and many people got intensive chemotherapy, Kadia concluded. We are fortunate now to live in an era where we have nine new drugs approved just in the last five years.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Read the rest here:
Treatment of AML in Older Patients Almost At 'The Holy Grail' - Curetoday.com

8 Tips for Coping With a Diagnosis of PPMS – Everyday Health

Primary-progressive multiple sclerosis (PPMS) is known for being an especially debilitating form of multiple sclerosis in which disability steadily worsens over time, sometimes quickly. This form of MS affects about 10 to 15 percent of people diagnosed with multiple sclerosis.

Typically, people with PPMS do not have distinct periods of relapse or remission, as is the case with more common form of MS, relapsing-remitting MS.

While there are approaches for controlling the symptoms of PPMS, treatments for the condition are limited: Only one medication, Ocrevus (ocrelizumab), has been approved by the U.S. Food and Drug Administration (FDA) for slowing the progression of PPMS.

RELATED: 10 Essential Facts About Primary-Progressive MS

Because PPMS is progressive and often disabling, receiving a diagnosis can be traumatic.

Beth Broun, a New York City native who now lives upstate, received her diagnosis 10 years ago. The 56-year-old first noticed something was wrong when her left leg began feeling weak, and she started tripping over her left foot.

My husband and I were walking on the Upper West Side [of Manhattan], and my left foot completely flopped, Broun says.

Her primary care physician sent her to a neurologist who was not an MS expert. He advised her to get physical therapy, but after six months nothing had changed.

It took her two years before she consulted another neurologist who ordered a brain scan and spotted the tell-tale signs of MS.

RELATED: Advances in Diagnosing Multiple Sclerosis

I freaked out, says Broun. She called her husband and told him the news and then did what she thought was the next most essential thing: I went to Bergdorf Goodman, and I bought a $3,500 handbag, because thats what you do when youre diagnosed.

After getting over the initial shock of the diagnosis, Broun started the gradual process of coming to terms her condition and then creating a plan to deal with the symptoms. Here are some tips that can help anyone who is newly diagnosed with PPMS.

As director of the MS Comprehensive Care Center at Stony Brook Neurosciences Institute, Patricia Coyle, MD,treats patients with PPMS and understands why a diagnosis is especially traumatic.

As you learn more about the disease, you realize that primary-progressive MS is a more significant form, where there is basically inevitable disability, says Dr. Coyle.

Coyle stresses, however that an education program is extremely important, because it can reduce fears. The more people know, the better they are able to deal with the illness and to find the information they need about therapies and disease progression that can provide them with the hope to go on and develop coping skills to live with the illness.

Coyle says that people need to know that they can clinically stabilize, sometimes for up to several years, and they can even see some improvement its in the minority, but that can occur.

Because the pace of worsening of PPMS doesnt tend to change over time, people who have it have some idea of what to expect from year to year.

Still, its important to have medical providers who can talk with you about what youre experiencing.

I think you want to have a relationship with your healthcare providers where you are free to ask any questions that you have, Coyle says.

A good starting point to find answers to commonly asked questions about PPMS is the National Multiple Sclerosis Society (NMSS). The website of the Multiple Sclerosis Association of America is another good place to find authoritative information about the various types of MS, including PPMS.

But, Broun cautions, dont automatically trust all of the advice or assertions about MS that you might read online, even when a person appears to write with great authority. Some of what she read along the way convinced her that she might go blind or lose her ability to speak. Having a medical provider who can help you sort out whats real and whats not can be a big help in these situations.

Along these lines, Coyle cautions about internet scams that promise miracle cures and prey on desperate patients.

If you read, We have stem cells that will improve your MS; you only need to pay $20,000, that's not legitimate, she says. There is no documented stem cell treatment for MS at this point in time.

Having PPMS doesnt mean you have to stop working. Its symptoms and progression are unique to each individual, so the illness doesnt have to mean an end to career.

In an article for Roche Pharmaceuticals, professor Jrme de Seze, PhD, the department head of the Neurology and Clinical Investigation Centre at the University of Strasbourg in France, wrote that most PPMS patients he deals with are keen to keep working.

Coyle emphasizes that a diagnosis doesnt have to be a career-ender. While this is a more severe form of MS, people can still continue to function for prolonged periods of time, she says.

Because some of the symptoms such as fatigue and cognitive impairment may limit ones ability to work, an individual may seek to work part-time.

The NMSS provides a legal guide for people with MS that addresses many workplace-related questions, such as "Am I obligated to tell my employer about my MS diagnosis?" and "Can I be let go from my job because of my MS?"

Work situations are always going to vary, but Coyle notes that some employers may be sympathetic.

An informed employer could actually be potentially very helpful with regard to accommodations, she says.

RELATED: 6 Top Tech Recommendations for Primary-Progressive MS

Broun says that the No. 1 thing to do is to put together a trusted health support team. This can include a neurologist, primary care provider, physical therapist, and mental health professional.

In Brouns case, it took some trial and error to find an MS care provider who felt right for her. But after consulting with different specialists, Broun found that Saud Sadiq, MD, a neurologist at the Tisch MS Research Center in New York City, provides guidance and treatment options that she believes in.

RELATED: Shared Decision-Making for MS Treatment

A mental health professional can be a key member of your health support team.

Its not uncommon for patients early in diagnosis to go through an adjustment period of anxiety and some depression when they hear they have MS, says Laura Safar, MD, an assistant professor of psychiatry at Brigham and Womens Hospital in Boston and a psychiatrist who treats psychiatric disorders among people with multiple sclerosis. Patients may have fears about their prognosis, and questions about what their progression will be like.

Individuals cope in different ways, Dr. Safar says. Some of them can be very proactive and want to learn about everything they can do to improve their health. Others can be overwhelmed, and avoid dealing with the diagnosis and treatment.

Safar says that it can be helpful for clinicians to observe how different patients cope with their illness to understand what type of support or interventions they need in addition to educating them about the diagnosis and next steps for treatment.

Doctors and patients alike should be aware that PPMS can affect a persons cognition, or their ability to think, remember, and perform other mental tasks.

Depending on a persons needs, appropriate interventions may include a neuropsychological evaluation to assess cognition, or a referral to a psychotherapist or psychiatrist to focus on emotional and coping issues. Mental health therapy may involve both talking through problems and taking antidepressants.

Rehabilitation therapies including physical, occupational, and cognitive rehabilitation can be tools to sustain and improve a patient's cognitive and functional abilities.

From a psychological perspective, rehabilitationstrategies, when combined with disease-modifyingtreatment, can assist in providing a sense of mastery over their illness, she says.

Ultimately, Safar says that her goal is to help individuals figure out how do I make this illness a part of my life, but not let it define the whole of who I am and what my life is about.

Safar notes that ideally, friends and family members should be part of the support network a person with MS relies on.

I want to make sure that people are not isolated and not alone, she says. So I find out if they have friends or family they can talk to about their diagnosis.

Safar recognizes that for some it can be difficult to even share they are ill. They are concerned that a partner may not be supportive or may turn away. Or they fear that they will cause too much worry among family members. They want to protect their loved ones and their relationships, she says.

Because she firmly believes that patients should not take this on alone, she advises some to take gradual steps toward disclosing information about the diagnosis and see how people close to them react.

RELATED: How MS Contributes to Isolation and What You Can Do to Stay Connected

In addition to seeking emotional support from friends and family, people with PPMS may also want to connect with one or more online groups.

Through participating in several MS groups on Facebook, Broun developed a deep friendship with another person with PPMS who lives in the Netherlands, and they each push the other to be proactive about their illness.

We say were going to fight each other; were going to outrun each other, she jokes. Hes a force.

For those looking for online support and connection, Broun suggests exploring Moodify, the PPMS Facebook page, as well as the International Progressive MS Alliance.

While looking after your mental state is vital to living with PPMS, so is doing your best to maintain good physical health. Broun gets around nowadays with a walker. She says its brutal to see herself in the mirror that way, but without exercise, she might not even be walking.

Exercise is the No. 1 thing to me, says Broun.

When she was first diagnosed, Broun began working with a physical therapist to maintain mobility and function. She started doing leg presses and walking on an uphill treadmill for 10 minutes to build strength in her glutes, hip flexors, and hamstrings.

Currently, she meets with a personal trainer two times a week to work on her muscle strength and balance, which she describes as incredibly weak. Because Broun has foot drop (difficulty lifting the front part of her foot), she does special exercises to keep her foot up.

My favorite exercise, which may not be specific forMS but makes me feel dynamite, is riding a spin bike, says Broun. You would never know I have a MS when Im riding it, but as soon as I get off I can barely walk. I love the confidence and ego boost I get from it.

On her visits with Dr. Sadiq, she also works with a new therapist on a special robotic machine, which helps someone like me use muscles I havent used in years.

To get started with exercise on your own, the Multiple Sclerosis Trustprovides a series of strength, stretching, balance, and breathing exercises for people with MS to explore and use to build their own routine for physical activity.

Following a healthy diet is also important for maintaining strength and stamina. For Broun, this means sticking to a Mediterranean-type diet, primarily consisting of organic proteins and vegetables.

At the end of the day, says Broun, I can control my exercising, and I can control what I can eat to feel good otherwise, MS is an animal, and its going to take over my body.

Coyle recommends exploring the many MS apps on the market for tracking symptoms and other purposes.

Apps have a number of different functions they can help track activities, track what youre doing in terms of exercise, and enable you to easily look up information related to MS, she says.

The Multiple Sclerosis Clinical Care App, for example, contains current information on the diagnosis, classification, and management of multiple sclerosis (MS), concisely presented for use at the point of care.

Several appsare available that allow you to track symptoms, notes TeamScope. My MS Manager, created and supported by the Multiple Sclerosis Association of America, is one such example.

The National MS Society recommends Happy the App, a 24/7 phone-based emotional support service via mobile app that connects individuals experiencing everyday stresses, struggles, anxiety, or loneliness with exceptionally compassionate listeners.

Read the original post:
8 Tips for Coping With a Diagnosis of PPMS - Everyday Health

More positive results from CRISPR trial for sickle cell and thalassaemia – BioNews

16 August 2021

A genome editing-based gene therapy forblood diseasessickle cell disease andbeta-thalassaemia continues to be effective more than two years after treatment.

The clinical trial for the therapy, named CTX001, previously reported good preliminary results (see BioNews 1052) and new data was presented at the European Haematology Association 2021 Virtual Congress.

'We are hearing that it is life-changing.' said Professor Stephan Grupp from the Cell and Gene Therapy Laboratory at Children's Hospital of Philadelphia, one of the researchers collaborating on the trial.

Patients with sickle cell disease or beta-thalassaemia carry a mutation in a single gene that causes problems in an essential blood molecule called haemoglobin. Patients usually require lifelong blood transfusions, sometimes stem cell transplants, as well as ongoing pain management. Sickle cell disease can also impact reproductive health in women (see BioNews 1105).

This clinical trial involved taking a patient's own blood stem cells, called hematopoietic stem cells, and editing them outside the body.CRISPR/Cas9 genome editing wasused to reactivatea different haemoglobin gene that is usually only expressed in the fetus and is switched off at birth. The editedstem cells were transplanted back into thepatients, who started producing fetal haemoglobin,replacingthe nonfunctional haemoglobin that causeddisease symptoms.

'The data presented today in 22 patients are impressive in both the consistency and durability of effect. These results add to the growing body of evidence that CTX001 may hold the promise for a one-time functional cure for sickle cell disease and beta-thalassemia.' said Dr Reshma Kewalramani, CEO of Vertex Pharmaceuticals in Boston, Massachusetts, who developed the treatment in partnership with CRISPR Therapeutics from Zug, Switzerland.

Aftertwo years post-gene therapy, the sickle cell disease patients were reported to be free of vaso-occlusive crises; a painful organ injury occurring when blood cells cause blockages, common to sickle cell disease patients. None of the beta-thalassaemia patients has required any further blood transfusions as all have started producing functional levels of fetal haemoglobin in their blood.

'The evidence so far indicates that it is durable in the time frame we've seen, and we just have to continue to follow the patients' said Professor Grupp.

See original here:
More positive results from CRISPR trial for sickle cell and thalassaemia - BioNews

Diabetic patient receives stem cell therapy – The Hindu

In a pioneering off-the-shelf drug treatment in place of a surgical procedure, Maruti Hospital on Tuesday inaugurated its Regenerative Medicine Department by administering stem cell therapy for a diabetic patient who lost four toes on both feet.

Developed by pharma major, Cipla, in collaboration with Bengaluru-based, Stempeutics Research, over 14 years, it is available (on order) in vials of 150 million and 200 million cells harvested from healthy individuals and costs between 1.5 to 2 lakh.

Diabetic foot ulcers/critical limb ischemia prevents the leg and feet from receiving adequate oxygen and nutrients needed for proper function. The stell cells are injected into the affected leg to promote new blood vessels growth called angiogenesis. It helps avoid amputation if given before gangrene sets in.

Stem cell treatment will help to improve blood circulation in the feet of the patient. The new method allows patients from any place to access this treatment in a ready-to-use procedure. We hope to use customised variations of this therapy for people with other medical ailments in the future, and reduce the dependence on transplants, said V. R. Ravi, orthopaedic surgeon, Maruti Hospital, said addressing the media.

The drug was produced in a carefully monitored processes, with mesenchymal stromal cell derived from the bone marrow of healthy donors in the age group of 20-25 years. It was transported from Bengaluru to Tiruchi by car with liquid nitrogen packs to keep the drug chilled. It was brought to room temperature within four hours and used on the patient.

B.N.Manohar, Managing Director and Chief Executive Officer, Stempeutics, was also present.

Read the original:
Diabetic patient receives stem cell therapy - The Hindu

COVID- 19 Third Dose Approved for Certain Immunocompromised Individuals – the City of Cambridge

Home > COVID-19 Information > News > COVID- 19 Third Dose Approved for Certain Immunocompromised Individuals

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) recently approved an additional third dose of the COVID-19 vaccine for certain people who are immunocompromised due to a medical condition or because they are receiving medications or treatments that weaken their immune response.

The specific conditions and treatments include but are not limited to:

People who are immunocompromised are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness, and may benefit from an additional dose to make sure they have enough protection against COVID-19. The CDC recommendation applies to immunocompromised people who received one of the mRNA vaccines (Pfizer or Moderna) and not the one-shot Johnson & Johnson vaccine (J&J).

Cambridge residents who have questions about whether a third dose of vaccine is recommended should contact their medical provider to discuss these recommendations.

Additional information may be found on the CDCs website here.

Here is the original post:
COVID- 19 Third Dose Approved for Certain Immunocompromised Individuals - the City of Cambridge

3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along…

VANCOUVER, BC, Aug. 17, 2021 /PRNewswire/ -- The global 3D bioprinting market size is expected to reach USD 2,687.8 Million in 2027 at a CAGR of 20.7% during the forecast period, according to the recent report by Emergen Research. Rapid technological advancements in 3D bioprinters, increasing investment to accelerate research and development activities of bioprinters, and rising use of 3D bioprinters to develop biomaterials for drug research and regeneration of joints and ligaments are key factors expected to drive market revenue growth over the forecast period. In addition, numerous advantages of 3D bioprinting in organ reconstruction to treat various end-stage disorders is another key factor contributing to the revenue growth of the market.

Emergen_Research_Logo

3D bioprinting leverages techniques similar to additive manufacturing to mix up growth factors, cells, and biomaterials to create biomedical parts that can mimic natural tissue attributes. 3D bioprinting leverages layer-by-layer technique to add materials called as bioinks to create tissue-like structures that can be used in medical and tissue engineering procedures. Recent advancements in the technique has expanded its scope in drug design and development by creating target tissues and cells for drug research and testing. In addition, 3D bioprinters can be used to reconstruct tissues from any body part and this has further increased its applications for treating various severe and chronic disorders. Significant progress in tissue engineering and production of biomaterials have contributed considerably to the 3D bioprinting market growth.

Download FREE Sample Brochure (Customized Sample PDF File delivered as per your specific requirement)@ https://www.emergenresearch.com/request-sample/133

3D bioprinters have been extensively used in vaccine research during the COVID-19 pandemic. Bioprinting is widely being used in the development of regenerative medicines, stem cell therapies, drug research and therapies, and tissue and organ reconstruction. Increasing application of 3D bioprinting in cosmetic and pharmaceutical sector is also a key factor contributing to the revenue growth of the market going ahead. However, lack of skilled professionals and technical knowledge, high costs of 3D bioprinting, and limited access to advanced technologies in developing and underdeveloped countries are some key factors expected to restrain market growth to a significant extent over the forecast period.

Story continues

Some Key Highlights in the Report:

Inkjet-based printing segment is expected to account for largest revenue share over the forecast period owing to increasing adoption of ink-jet-based printing in healthcare industry for biofabrication of tissues and cells and in drug delivery approaches owing to its cost-effectiveness, higher reliability, and increased efficiency.

Living cells segmented accounted for a significantly large revenue share in the global market in 2019 and is expected to register considerable revenue growth going ahead owing to increasing use of living cells in stem cell research and regenerative medicine.

Research application dominated other segments in terms of revenue in 2019 and is expected to register robust revenue CAGR over the forecast period owing to increasing investment to accelerate R&D activities, rapid progress in stem cell research, and growing demand for regenerative medicine owing to increasing incidence of chronic diseases.

North America market revenue is expected to expand significantly over the forecast period owing to establishment of state-of-the-art healthcare facilities, increasing R&D activities in stem cell and regenerative medicine, rising investment by public and private organizations, and presence of key players in the region.

Asia Pacific is expected to register robust revenue CAGR over the forecast period owing to increasing demand for tissue and organ transplants, growing preference for cosmetic surgeries, and increasing investment to boost drug research and development.

Key companies in the market include Allevi Inc., Organovo Holdings, Inc., CELLINK, Aspect Biosystems Ltd., Cyfuse Biomedical K.K., EnvisionTEC GmbH, TeVido BioDevices, Poietis, Digilab, Inc., and Nano3D Biosciences, Inc, among others.

In July 2021, T&R Biofab, which is a Korean 3D printer manufacturer, announced successful fabrication of liver tissues and translation into an animal test subject for the first time ever in a groundbreaking research step. Leveraging the firm's 3DX bioprinter, researchers have been able to develop spherical microtissues into structures that can replicate the "lobules" found in human liver.

Buy your Exclusive copy [Make Payment ]@ https://www.emergenresearch.com/select-license/133

For the purpose of this report, Emergen Research has segmented the global 3D bioprinting market on the basis of technology, material, application, and region:

Technology Outlook (Revenue, USD Million; 2017-2027)

Laser-based

Inkjet-based

Syringe-based

Magnetic Levitation

Others

Material Outlook (Revenue, USD Million; 2017-2027)

Hydrogels

Living Cells

Extracellular Matrices

Others

Application Outlook (Revenue, USD Million; 2017-2027)

Clinical Application

Research Application

Have a look at Report Description and Table of Contents of Market Research Report@ https://www.emergenresearch.com/industry-report/3d-bioprinting-market

Regional Outlook (Revenue, USD Million; 2017-2027)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Explore more reports offered by Emergen Research:

The Global Oncology Informatics Market size was valued at USD 4.62 Billion in 2019 and is anticipated to reach USD 8.01 Billion by 2027 at a CAGR of 7.1%. An increase in the awareness of the different types of treatment options for oncology will drive the demand for the oncology informatics market. The major driving factor is the rise in the prevalence of cancer and heavy investment by the government institutes and research organizations.

The Global Nerve Repair and Regeneration Market size was valued at USD 6.05 Billion in 2019 and is forecasted to reach USD 11.62 Billion by 2027 at a CAGR of 9.0%. The market is mainly driven by the rising geriatric population and the increasing prevalence of nerve injuries. The high incidence of neurological disorders among the growing population is expected to drive the Nerve Repair and Regeneration Market growth.

The Global Spinal Fusion Devices Market size was valued at USD 6.88 Billion in 2019 and is forecasted to reach USD 8.90 Billion by 2027 at a CAGR of 3.5%. The market is mainly driven by the increasing aging population and their growing need for spine care. Advancements in surgical technology is a key contributing factor behind the increasing demand for spinal fusion devices over the forecast period.

The Global Interventional Oncology Devices Market size was valued at USD 1.92 Billion in 2019 and is expected to reach USD 3.11 Billion by 2027 at a CAGR of 6.6%. The global Interventional Oncology Devices market is forecasted to expand exponentially owing to the rising preference for minimally invasive surgical procedures. The increasing government initiatives to support Interventional Oncology is anticipated to further propel the market growth over the forecasted timeframe.

The global spinal implants and surgery devices market size was valued at USD 10.22 Billion in 2019 and is forecasted to reach USD 14.70 Billion by 2027 at a CAGR of 4.6%. The spinal implants and surgery devices market is observing high demand owing to factors including the rising occurrence of spinal disorders, a rise in the elderly population, growing inclination for less invasive surgery, and growing research activities for developing technologically updated in spinal devices.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:Eric Lee Corporate Sales Specialist Emergen Research | Web: http://www.emergenresearch.com Direct Line: +1 (604) 757-9756 E-mail: sales@emergenresearch.com Facebook | LinkedIn | Twitter | Blogs

Read Full Press Release@ https://www.emergenresearch.com/press-release/global-3d-bioprinting-market

Cision

View original content:https://www.prnewswire.com/news-releases/3d-bioprinting-market-size-to-reach-usd-2-687-8-million-in-2027--increasing-use-of-3d-bioprinters-in-medical-procedures-training-and-testing-along-with-organ-engineering-and-regenerative-medicine-are-some-key-factors-driving-ind-301356592.html

SOURCE Emergen Research

More here:
3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along...

Acute Myeloid Leukemia Treatment: What You Need to Know – Healthline

The umbrella term of leukemia encompasses several distinct types of leukemia, including acute myeloid leukemia (AML).

In 2021, its estimated that over 20,000 new cases of AML will be diagnosed, according to the National Cancer Institute (NCI). Since treatment varies depending on the specific kind of leukemia present, an accurate diagnosis is crucial.

There are a variety of treatments for AML. Your doctor will explain them and help choose a treatment plan based on the type of cancer you have and your individual situation.

Read on to learn more about the various treatment options for AML.

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. It affects white blood cells (WBCs), making them abnormal. In some forms of AML, they may also multiply very quickly.

Other names for AML include:

Read this for more information about AML.

Once the diagnosis is confirmed, your healthcare team will develop a plan to treat AML. Depending on the specific type and stage of AML, you may receive one or more of these treatments:

Chemotherapy is the main form of treatment for AML. Its divided into two phases:

Since AML can progress quickly, treatment is usually started as soon as possible after diagnosis. Other treatments may be used as well.

Chemotherapy, also called chemo, is the use of anti-cancer drugs to treat cancer. This is the main treatment for AML.

These drugs can be injected into a vein or under the skin, allowing the chemotherapy to travel through the bloodstream to attack cancer cells throughout the body. If leukemia has been found in the brain or spinal cord, chemo medication may be injected into the cerebrospinal fluid (CSF).

Chemo medications most often used to treat AML include:

Other chemo medications may include:

Side effects of chemotherapy can vary depending on the drug, dosage, and duration. They can include:

While chemotherapy is the main treatment for AML, for a subtype of AML called acute promyelocytic leukemia (APL), other non-chemotherapy drugs are more effective.

APL is caused by a specific gene mutation that affects WBCs. Some medications work better than chemo to help those cells develop normally. Two of these medications are:

ATRA can be given with chemotherapy or with ATO for the initial treatment of APL. Both drugs can also be given during consolidation.

Side effects of ATRA include:

Side effects of ATO can include:

Radiation therapy uses high-energy radiation to kill cancer cells. While its not the main treatment for those with AML, it can be used in treating AML. In AML, the radiation used is external beam radiation, which is similar to an X-ray.

Radiation can be used in AML to treat:

Side effects of radiation can include:

Surgery is rarely used in AML treatment. Leukemia cells are spread through the bone marrow and blood, making the condition impossible to improve with surgery. On rare occasions, a tumor or mass related to leukemia may form that may be treated with surgery.

Prior to chemotherapy, a small surgery to place a central venous catheter (CVC) or a central line, is often done. During this procedure, a small flexible tube is placed into a large vein in the chest. The end of it is either right under the skin or sticks out in the chest or upper arm.

Having a central line installed allows the treatment team to give intravenous medication and chemotherapy through the CVC, and to draw blood from it, reducing the number of needle sticks an individual has to have.

While chemotherapy is the main treatment for AML, it has its limits. Since high doses of these medications are toxic, the dosage must be limited. A stem cell transplant allows for higher doses of chemotherapy medications.

In a stem cell transplant, very high doses of chemotherapy medications, sometimes combined with radiation, are given. All of the individuals original bone marrow is destroyed on purpose.

Once this stage of therapy is over, blood-forming stem cells are given. These stem cells will grow, rebuilding the bone marrow. Healthy, cancer-free stem cells replace the destroyed bone marrow.

Read this article for more information about a stem cell transplant.

Targeted therapy drugs are medications that target only certain parts of cancer cells. They can be very effective for some people with AML. Most targeted therapy drugs are taken orally, except for gemtuzumab ozogamicin (Mylotarg), which is given as an intravenous infusion.

Talk with your treatment team about the potential side effects of each drug and what you should watch for when taking it. Some targeted therapy medications include:

One type of targeted therapy medication called FLT3 inhibitors targets the FLT3 gene. In some people with AML, a mutation in the FLT3 gene causes the creation of a protein, also called FLT3, that enables cancer cells to grow. Drugs in this category include:

Side effects of these drugs may include:

In some people with AML, there is a mutation in the IDH2 gene. These mutations stop bone marrow cells from maturing in a normal way. Medications called IDH inhibitors block IDH proteins produced by these mutated genes, allowing these bone marrow cells to grow normally and remain healthy.

Drugs in this category include:

Side effects can include:

AML cells contain a protein called CD33. A medication called gemtuzumab ozogamicin (Mylotarg) attaches to this CD33 protein and helps deliver chemotherapy medications directly to cancer cells so that these drugs are more effective.

Common side effects include:

There are less common but serious side effects like:

Venetoclax (Venclexta) is a BCL-2 inhibitor. This drug targets BCL-2, which is a protein that helps cancer cells live longer. The drug stops the BCL-2 protein from helping cancer cells survive so that these cancer cells die sooner. This medication can be used along with other chemotherapy drugs.

Side effects include:

AML can cause cellular mutations that prevent cells like bone marrow cells from developing and functioning normally. These mutations may affect the pathway cells use to send necessary signals. This pathway is called hedgehog. For some people with AML, especially those over age 75, strong chemo medications may be so harmful that chemo is not an option. For these individuals, a medication called, Glasdegib (Daurismo), may help them live longer. This medication helps stop the mutations and allows bone marrow cells to function normally.

Side effects of this medication may include:

Refractory AML happens when an individual is not in remission even after one to two cycles of induction chemotherapy, which means they have a blast count of 5 percent or more. Ten to 40 percent of people with AML have refractory AML.

If treatment isnt successful with one course of chemo, another one may be done. If a person is still not in remission after the second course of chemo, they may be given other medications or an increased dose of their current chemotherapy medications.

Other treatment options include stem cell transplant or a clinical trial of new therapies.

When an individual has no evidence of disease after treatment, its called remission or complete remission. Remission means these three criteria are met:

If there is no evidence at all of leukemia cells in the bone marrow, using highly sensitive tests, its called complete molecular remission. Minimal residual disease (MRD) occurs when, after treatment, leukemia cells cannot be seen in the bone marrow with standard tests but more sensitive tests like PCR tests do find leukemia cells.

Even after an individual has entered remission, they will likely need follow-up care and will need to be monitored by their doctor and healthcare team. This may mean additional tests, more frequent physical exams, and other care.

Although chemotherapy is the main treatment for AML, there are a variety of treatment options, depending on the AML subtype or whether you have a specific mutation. Treatment also depends on your response to initial treatment and whether or not remission is sustained.

Your treatment team will explain all of your treatment options and help you choose the treatment plan that is best for you and your individual situation.

View post:
Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline

Stem Cell Alopecia Treatment Market Size, Demand, Growth, Trends, Segmentation and Forecasts to 2028 – The Market Writeuo – The Market Writeuo

New Jersey, United States,-Verified Market Research recently released a new report titled Stem Cell Alopecia Treatment MarketSize Report, Growth and Forecast 2021-2028, Breakdown Data by Company, Key Regions, Types and Applications. The report has been compiled using primary and secondary research methodology that will provide a precise and precise understanding of the Stem Cell Alopecia Treatment market. Analysts used a top-down and bottom-up approach to assess the segments and properly assess their impact on the Stem Cell Alopecia Treatment market. The report offers a market overview which briefly describes the market situation and major segments. It also mentions the best players represented in the Stem Cell Alopecia Treatment market.

The 2021 report offers an in-depth analysis of each sector of this Stem Cell Alopecia Treatment industry. Fill in historical Stem Cell Alopecia Treatment data according to customer requirements. It offers Stem Cell Alopecia Treatment market research globally and locally. The detailed segment and manufacturer information of Stem Cell Alopecia Treatment helps guide future benefits and make important decisions for the growth of Stem Cell Alopecia Treatment.

Get | Download Sample Copy with TOC, Graphs & List of Figures @https://www.verifiedmarketresearch.com/download-sample/?rid=15102

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem, Sanford Burnham Prebys Medical Discovery Institute.

Stem Cell Alopecia Treatment Market Segmentation

Stem Cell Alopecia Treatment Market, By Indication

Male Pattern Baldness Female Pattern Baldness Others

In the next chapters, the research report reveals the development of the Stem Cell Alopecia Treatment market segments. Analysts have segmented the market on the basis of product, application, end-users, and geography. Each segment of the Stem Cell Alopecia Treatment market has been studied with in-depth insight. Analysts have evaluated the changing nature of the market segments, growing investments in manufacturing activities, and product innovation that are likely to impact them. In terms of geography, the report studies the changing political environment, social upliftment, and other government initiatives that are expected to contribute to the regional markets.

Get Discount On The Purchase Of This Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102

Stem Cell Alopecia Treatment Market Report Scope

Geographic Segment Covered in the Report:

North America (USA and Canada) Europe (UK, Germany, France and the rest of Europe) Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region) Latin America (Brazil, Mexico, and the rest of Latin America) Middle East and Africa (GCC and rest of the Middle East and Africa)

Key questions answered in the report:

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/

Visualize Stem Cell Alopecia Treatment Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Stem Cell Alopecia Treatment Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website:- https://www.verifiedmarketresearch.com/

View original post here:
Stem Cell Alopecia Treatment Market Size, Demand, Growth, Trends, Segmentation and Forecasts to 2028 - The Market Writeuo - The Market Writeuo

Some Residents Should Consider Third COVID-19 Vaccine Dose – Wyoming Department of Health

August 17, 2021

A third vaccine dose is now being recommended for a limited group of Wyoming residents with certain medical conditions, according to the Wyoming Department of Health (WDH).

Dr. Alexia Harrist, state health officer and state epidemiologist with WDH, said the Centers for Disease Control and Prevention (CDC) recommends people with moderately to severely compromised immune systems should receive an additional dose of Pfizer or Moderna COVID-19 vaccines.

National experts are seeing that people who are moderately to severely immunocompromised are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness, Harrist said. An additional dose of the Pfizer or Moderna vaccines can help these people make sure they have enough protection against COVID-19.

Harrist said those who should consider an additional vaccine dose at this time include people who have:

Added doses have NOT yet been authorized or recommended and are not available at this time for people without compromised immune systems or who may have received the one-dose Johnson and Johnson vaccine.

The additional dose for people with compromised immune systems should be administered at least 28 days after the original vaccination series is completed. Residents with questions on whether they should consider the additional dose are encouraged to discuss the recommendation with their regular medical professional.

More important details about the current third-dose recommendation from the CDC can be found at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.

The authorized vaccines each continue to offer solid protection from infection for Wyoming residents, including against the Delta variant, Harrist said.

An updated WDH review of more than 7,000 lab-confirmed and probable cases identified among Wyoming residents age 18 and older between May 1 and August 10 shows just over 95 percent of the individuals did not report being fully vaccinated against COVID-19. During the same period, of the nearly 350 persons infected by COVID-19 who were hospitalized at the time they were interviewed by public health representatives, just under 95 percent did not report being fully vaccinated against COVID-19.

Harrist continues to encourage residents to seek out free, safe and effective COVID-19 vaccines, which remain readily available across Wyoming. As always, we will continue sharing information about future vaccine-related recommendations, she said.

Convenient ways to find where to get COVID-19 vaccines include:

A person is considered fully vaccinated two weeks after two doses of either the Pfizer or Moderna vaccine or two weeks after one dose of the Johnson and Johnson (Janssen) vaccine.

More information from WDH about vaccination in Wyoming can be found at https://health.wyo.gov/publichealth/immunization/wyoming-covid-19-vaccine-information/.

Read the rest here:
Some Residents Should Consider Third COVID-19 Vaccine Dose - Wyoming Department of Health

Head-To-Head Phase 3 Trial To Evaluate BTK Inhibitors in MCL – Targeted Oncology

The open-label, randomized BRUIN trial will compare LOXO-305 to investigators choice of either ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa). Approximately 500 patients will be enrolled in the study.

"MCL patients who have been treated with a covalent BTK inhibitor have very few therapeutic options, and outcomes are extremely poor. LOXO-305 has demonstrated a promising efficacy profile in these patients, a setting where we urgently need new therapies," said Michael Wang, MD, Puddin Clarke Endowed professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, in a press release.

The primary end point of BRUIN is progression-free survival (PFS), and the secondary end points include event-free survival, time to treatment failure, time to worsening of MCL-related symptoms, comparative tolerability, overall response rate (ORR), duration of response, and overall survival.

A confirmed diagnosis of MCL is required for inclusion in the study as well as being previously treated with at least 1 prior line of systemic therapy for MCL, having measurable disease per Lugano criteria, having an ECOG performance status of 0 to 2, and having adequate laboratory values at baseline.

In the case of prior treatment with an FDA-approved or investigational BTK inhibitor, patients are ineligible to enroll in the study. According to the criteria, patients are also excluded if they have a history of bleeding diathesis, stroke, or intracranial hemorrhage within 6 months of randomization, and prior allogeneic stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T-cell therapy within 60 days of randomization. In addition, patients with significant cardiovascular disease, and other comorbidities that may interfere with study treatment are not eligible to enroll.

Treatment with LOXO-305 has already shown promise for the treatment of 323 patients with previously treated B-cell malignancies. In the phase 1/2 BRUIN study, the use of the agent was investigated in patients with MCL, chronic lymphocytic leukemia/small lymphocytic leukemia, Waldenstroms macroglobulinemia (WM), and other B-cell malignancies. The patients were pretreated with a BTK inhibitor (95%), anti-CD20 antibody (98%), chemotherapy (92%), lenalidomide (Revlimid; 20%), autologous transplant (25%), CAR T-cell therapy (5%), and ASCT.3

According to data presented during the 2020 American Society of Hematology Annual Meeting, the ORR observed with LOXO-305 in 59 efficacy-evaluable patients from the MCL cohort was 52% (95% CI, 38%-65%), which included 14 complete and 15 partial responses. The median time to the first response in these patients was 1.8 months.

In the WM cohort of 19 efficacy-evaluable patients, the ORR observed was 68% (95% CI, 44%-87)%, which notably was similar in patients who were previously treated with a BTK inhibitor (69%; 95% CI, 39%-91%). Further, 4 out of 8 patients with follicular lymphoma had a response to LOXO-305, in addition to 75% of the evaluable Richter's transformation cohort, and 8 out of 35 patients with other B-cell malignancies, including diffuse large B-cell lymphoma and marginal zone lymphoma.

The most commonly reported adverse events (AEs) with LOXO-305 in the phase 1/2 BRUIN study were fatigue (20%), diarrhea (17%), and contusion (13%). Eight percent of patients had dose interruptions due to AEs, while 2.2% had dose reduction, and 1.5% permanently discontinued treatment with LOXO-305.

LOXO-305 was designed to overcome some of the limitations seen with current BTK therapies and we believe the promising efficacy and tolerability data demonstrate its potential to be an important new treatment option for MCL patients, said David Hyman, MD, chief medical officer of Loxo Oncology at Lilly, in a press release.

References:

1. Mato AR, Pagel JM, Coombs CC, et al. 542LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: results from the phase 1/2 bruin study. . Presented at: 2020 ASH Annual Meeting and Exposition. December 4-8, 2020; Virtual. Abstract 542.

2. Study of BTK inhibitor LOXO-305 versus approved BTK inhibitor drugs in patients withmantle cell lymphoma(MCL) (BRUIN-MCL-321). Clnicaltrials.gov. Accessed August 17, 2021. https://bit.ly/3CXTgu4

3. Loxo Oncology at Lilly announces updated data from the phase 1/2 BRUIN Clinical Trial for LOXO-305 in mantle cell lymphoma and non-Hodgkin lymphomas at the American Society of Hematology (ASH) Annual Meeting. News release. Loxo Oncology at Lilly. December 5, 2020. accessed August 17, 2021. https://prn.to/37QNw7a

Read more:
Head-To-Head Phase 3 Trial To Evaluate BTK Inhibitors in MCL - Targeted Oncology